Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children
Completed
Novo Nordisk A/S
Phase 3
2003-05-01
This trial is conducted in the United States of America (USA). This is a 12 month study to
determine if Norditropin is safe and effective in children with IGF deficiency.
Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease
Completed
Novo Nordisk A/S
Phase 2
2003-04-01
This trial is conducted in Asia, Europe, and Middle East. Adult patients with chronic kidney
disease are treated with growth hormone to assess effect on nutritional status.
Effect of Growth Hormone on Bone Mineral Density in Young Adults With Child-hood Onset Growth Hormone Deficiency
Completed
Novo Nordisk A/S
Phase 3
2002-02-01
This trial is conducted in Europe. Growth Hormone in young adults with growth hormone
deficiency in childhood. This trial compares a treated group of patients with an untreated
group of patients.
Albright Hereditary Osteodystrophy: Growth Hormone Trial and Cognitive/Behavioral Assessments
Recruiting
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase 2/Phase 3
2003-01-01
We, the researchers, have found that growth hormone deficiency is very common in patients
with pseudohypoparathyroidism type 1a, which falls under the broader condition termed
Albright hereditary osteodystrophy. Patients with pseudohypoparathyroidism type 1a typically
are short and obese. Some of these patients are not short during childhood, but due to a
combination of factors, they end up short as adults. We are evaluating the effect of growth
hormone treatment in those patients with pseudohypoparathyroidism type 1a who are found to
be growth hormone deficient. We hypothesize that growth hormone deficiency may contribute to
the short stature and obesity found in this condition. We are also evaluating the effect of
growth hormone on patients with pseudohypoparathyroidism type 1a who are not growth hormone
deficient (i.e., growth hormone sufficient) in those who had been on study drug through R01
FD003409 or who meet the criteria of idiopathic short stature or SGA.
We are also evaluating neurocognitive and psychosocial functioning in participants with AHO
in order to determine the specific impairments that are most common in the condition and to
determine the best approach toward management.
Funding source -- Growth hormone study: FDA OOPD [R01 FD003409 (which has ended) and R01
FD002568 (which has ended)] Cognitive/behavior: NICHD R21 HD078864
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
